{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:53:34Z","timestamp":1791597214342,"version":"4.3.4"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T00:00:00Z","timestamp":1451520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Respiratory syncytial virus (RSV) is an important causative agent of lower respiratory tract infections in infants and elderly individuals. Its fusion (F) protein is critical for virus infection. It is targeted by several investigational antivirals and by palivizumab, a humanized monoclonal antibody used prophylactically in infants considered at high risk of severe RSV disease. ALX-0171 is a trimeric Nanobody that binds the antigenic site II of RSV F protein with subnanomolar affinity. ALX-0171 demonstrated\n                    <jats:italic>in vitro<\/jats:italic>\n                    neutralization superior to that of palivizumab against prototypic RSV subtype A and B strains. Moreover, ALX-0171 completely blocked replication to below the limit of detection for 87% of the viruses tested, whereas palivizumab did so for 18% of the viruses tested at a fixed concentration. Importantly, ALX-0171 was highly effective in reducing both nasal and lung RSV titers when delivered prophylactically or therapeutically directly to the lungs of cotton rats. ALX-0171 represents a potent novel antiviral compound with significant potential to treat RSV-mediated disease.\n                  <\/jats:p>","DOI":"10.1128\/aac.01802-15","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T22:28:33Z","timestamp":1444084113000},"page":"6-13","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":273,"title":["Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection"],"prefix":"10.1128","volume":"60","author":[{"given":"Laurent","family":"Detalle","sequence":"first","affiliation":[{"name":"Ablynx nv, Zwijnaarde, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Stohr","sequence":"additional","affiliation":[{"name":"Ablynx nv, Zwijnaarde, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Palomo","sequence":"additional","affiliation":[{"name":"Centro Nacional de Microbiolog\u00eda and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A.","family":"Piedra","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian E.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Mas","sequence":"additional","affiliation":[{"name":"Centro Nacional de Microbiolog\u00eda and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrena","family":"Millar","sequence":"additional","affiliation":[{"name":"Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ultan F.","family":"Power","sequence":"additional","affiliation":[{"name":"Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catelijne","family":"Stortelers","sequence":"additional","affiliation":[{"name":"Ablynx nv, Zwijnaarde, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Allosery","sequence":"additional","affiliation":[{"name":"Ablynx nv, Zwijnaarde, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Melero","sequence":"additional","affiliation":[{"name":"Centro Nacional de Microbiolog\u00eda and CIBER de Enfermedades Respiratorias, Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Depla","sequence":"additional","affiliation":[{"name":"Ablynx nv, Zwijnaarde, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60206-1"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.11.5654-5666.2002"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1110203109"},{"key":"e_1_3_3_5_2","first-page":"147","article-title":"Biology of human respiratory syncytial virus: a review","volume":"3","author":"Aliyu A","year":"2010","unstructured":"Aliyu A, Ahmad A, Rogo L, Sale J, Idris H. 2010. Biology of human respiratory syncytial virus: a review. Bayero J Pure Appl Sci 3:147\u2013155.","journal-title":"Bayero J Pure Appl Sci"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/apa.12662"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.01.00254101"},{"key":"e_1_3_3_8_2","first-page":"433","article-title":"Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants","volume":"2","author":"Mejias A","year":"2008","unstructured":"Mejias A, Ramilo O. 2008. Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics 2:433\u2013439.","journal-title":"Biologics"},{"key":"e_1_3_3_9_2","first-page":"103","article-title":"Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab","volume":"317","author":"Wu H","year":"2008","unstructured":"Wu H, Pfarr DS, Losonsky GA, Kiener PA. 2008. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr Top Microbiol Immunol 317:103\u2013123.","journal-title":"Curr Top Microbiol Immunol"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.102.3.531"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-1665"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.8.6922-6928.1998"},{"key":"e_1_3_3_13_2","first-page":"209","article-title":"Systematic review of the biology and medical management of respiratory syncytial virus infection","volume":"48","author":"Black CP","year":"2003","unstructured":"Black CP. 2003. Systematic review of the biology and medical management of respiratory syncytial virus infection. Respir Care 48:209\u2013231.","journal-title":"Respir Care"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-79-9-2221"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-82-9-2117"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032807"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00115-09"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu473"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/363446a0"},{"key":"e_1_3_3_20_2","first-page":"1212","article-title":"The development of Nanobodies for therapeutic applications","volume":"10","author":"Van Bockstaele F","year":"2009","unstructured":"Van Bockstaele F, Holz JB, Revets H. 2009. The development of Nanobodies for therapeutic applications. Curr Opin Investig Drugs 10:1212\u20131224.","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2011.09.002"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir622"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017665"},{"key":"e_1_3_3_24_2","volume-title":"A multicentre study in otherwise healthy infants and toddlers hospitalized for and diagnosed with RSV lower respiratory tract infection to evaluate the safety, tolerability, and clinical activity of ALX-0171","author":"National Institutes of Health","year":"2015","unstructured":"National Institutes of Health. 18 June 2015, posting date. A multicentre study in otherwise healthy infants and toddlers hospitalized for and diagnosed with RSV lower respiratory tract infection to evaluate the safety, tolerability, and clinical activity of ALX-0171. National Institutes of Health, Bethesda, MD."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6750-7-17"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2071"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1234914"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.63.2.925-932.1989"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-73-9-2225"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-38919-1_3"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-8-43"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0090786"},{"key":"e_1_3_3_33_2","volume-title":"WC500056731 EPAR: initial scientific discussion for the approval of Synagis","author":"European Medicines Agency","year":"2004","unstructured":"European Medicines Agency. 2004. WC500056731 EPAR: initial scientific discussion for the approval of Synagis. European Medicines Agency, London, United Kingdom."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2005.04.049"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02699-09"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00447-10"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1723"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M102107200"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(01)01790-X"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181a165e4"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2007.02.024"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1086\/314523"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1402458111"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000000240"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.61.6.1851-1854.1987"},{"key":"e_1_3_3_46_2","first-page":"37","article-title":"ALX-0171: safety and therapeutic potential of an inhaled anti-RSV Nanobody","volume":"1","author":"De Bruyn S","year":"2015","unstructured":"De Bruyn S, De Smedt T, Allosery K, Crabbe P, De Brabandere V, Detalle L, Mortier K, Schoolmeester A, Wouters H, St\u00f6hr T, Depla E. 2015. ALX-0171: safety and therapeutic potential of an inhaled anti-RSV Nanobody. RDD Europe 2015 1:37\u201348.","journal-title":"RDD Europe 2015"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1994.1052"},{"key":"e_1_3_3_48_2","volume-title":"Inhalation studies: foundations and techniques","author":"Phalen R","year":"1984","unstructured":"Phalen R. 1984. Inhalation studies: foundations and techniques. CRC Press LLC, Boca Raton, FL."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01802-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01802-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:34:55Z","timestamp":1645457695000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01802-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1128\/AAC.01802-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01802-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2015-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-09-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-12-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}